


Meeting Report

NINTH MEETING OF VACCINE-PREVENTABLE DISEASES LABORATORY NETWORKS IN THE WESTERN PACIFIC REGION













































27 September–1 October 2021
Virtual meeting











































Ninth Meeting of Vaccine-Preventable Diseases Laboratory Networks in the Western Pacific Region (Poliomyelitis Session) 27-28 September 2021 - Virtual



Ninth Meeting of Vaccine-Preventable Diseases Laboratory Networks in the Western Pacific Region (Measles and Rubella Session) 29 September - 01 October 2021 - Virtual

 WHO- WPRO 3	 Mr David FEATHERSTON	 Dr Mick MULDER, W...	 Ms Vicki STAMBOS, VI...	 Dr Meik DILCHER, CHL...	 Ms Talica VAKACOLAT...	 Dr Julian DRUCE, VIDR...
 Dr Makoto TAKEDA, NI...	 Maria Christine OLART...	 Ms Venus IP, Macau	 Dr Paul ROTA, US CDC	 Aziyati OMAR, NPHL, ...	 Dr Mayan LUMANDAS, ...	 Dr Noriyuki OTSUKI, NI...
 Myungguk Han, KDCA, ...	 Dr Satoru ARAI, NIID, J...	 Dr Nur Diyana MASTO...	 Dr Rashidah MOHAM...	 Ms Mazmah Ahmad M...	 Qiangian Liu, China C...	 Yan Zhang-China CDC
 Chi WAI rickjason Chan	 Dr Mark PAPANIA, US ...	 Maria Theresa SALVAD...	 Dr Jennifer KNAPP, US...	 Dr Keiko TANAKA-TAY...	 Mr Benjamin BAYUTAS...	 Ms Analisa Bautista, W...
 Dianna BUGNON	 Ms Cherry GARCIA, W...	 Ms Cherry GARCIA, W...	 Dr Deog-Yong LEE, KD...	 Yoshio Mori, NIID, JAP...	 Ms Varja GRABOVAC, ...	 Sayaka Takanashi, NIID...
 Dr Yusmah MUHAMMAD	 Ms YANFEI Bai	 Josephine Logronio	 Ms XU Jing	 Dr Kamal HAIKAL bin ...	 Naiying Mao, China C...	 Kayla MARIANO

Recording... [Pause] [Stop]

 Dr Mark PAPANIA, US ...	 Maria Theresa SALVAD...	 Dr Jennifer KNAPP, US...	 Dr Keiko TANAKA-TAY...	 Mr Benjamin BAYUTAS...	 Ms Analisa Bautista, W...	 Dianna BUGNON
 Ms Cherry GARCIA, W...	 Ms Cherry GARCIA, W...	 Dr Deog-Yong LEE, KD...	 Yoshio Mori, NIID, JAP...	 Ms Varja GRABOVAC, ...	 Sayaka Takanashi, NIID...	 Dr Yusmah MUHAMMAD
 Ms YANFEI Bai	 Josephine Logronio	 Ms XU Jing	 Dr Kamal HAIKAL bin ...	 Naiying Mao, China C...	 Kayla MARIANO	 Dr Stephen CROOKE, ...
 Ms Leonibel REYES, RI...	 azma	 Dr ZHU Zhen, China C...	 Dr Grace Jie Yin Ngan...	 Ms Raydel ANDERSON...	 Gibson WOO, RRL/Hon...	 Dr Jinsook WANG, KC...
 Dr MINA Kim, KCDA, K...	 Ms Thuong Nguyen T...	 Dr Haruna MIWA, NIID...	 Ying Xiong, Jiangxi CD...	 Dr Saeko MORINO, NIID	 Huiling Wang-China C...	 Dr Lin CUI, NCID, Sing...
 Dr SunWhan PARK, KD...	 正帆 潘	 Mohd Sanusi Che Lah	 Wei Wang	 fengdaxing	 Ying Liu, China CDC	 Deborah Bettels

WORLD HEALTH ORGANIZATION
REGIONAL OFFICE FOR THE WESTERN PACIFIC

RS/2021/GE/16(virtual)

English only

MEETING REPORT

NINTH MEETING OF VACCINE-PREVENTABLE DISEASES
LABORATORY NETWORKS IN THE WESTERN PACIFIC REGION

Convened by:

WORLD HEALTH ORGANIZATION
REGIONAL OFFICE FOR THE WESTERN PACIFIC

Virtual meeting
27 September–1 October 2021

Not for sale

Printed and distributed by:

World Health Organization
Regional Office for the Western Pacific
Manila, Philippines

January 2022

NOTE

The views expressed in this report are those of the participants of the Ninth Meeting of Vaccine-Preventable Diseases Laboratory Networks in the Western Pacific Region and do not necessarily reflect the policies of the conveners.

This report has been prepared by the World Health Organization Regional Office for the Western Pacific for Member States in the Region and for those who participated in the Ninth Meeting of Vaccine-Preventable Diseases Laboratory Networks in the Western Pacific Region, held virtually from 27 September to 1 October 2021.

CONTENTS

SUMMARY	1
1. INTRODUCTION	2
1.1 Meeting organization	2
1.2 Meeting objectives	2
2. PROCEEDINGS	2
2.1 Polio Laboratory Network Meeting	2
2.1.1 Polio endgame strategy and updates on maintaining polio-free status	2
2.1.2 Reports from the Global Specialized Laboratory and regional reference laboratories	3
2.1.3 Reports from the national polio laboratories in the Region	4
2.1.4 Laboratory quality assurance system	6
2.1.5 New diagnostics, development and capacity-building	7
2.1.6 Global Polio Laboratory Network performance tools	8
2.1.7 Key pillars of the Global Polio Surveillance Action Plan (GPSAP) 2022–2023 to meet objectives of new GPEI Strategic Plan 2022–2026	9
2.2 Measles and Rubella Laboratory Network Meeting	9
2.2.1 Overview of global and regional measles and rubella elimination	9
2.2.2 Reports from the Global Specialized Laboratory and Regional Reference Laboratory reports	10
2.1.5 Country presentations	11
2.1.6 Issues in the Region	14
2.1.7 MeaNS and RubeNS update	14
2.1.8 Laboratory quality assurance systems	14
3. RECOMMENDATIONS	15
3.1 Recommendations for Member States	15
3.2 Recommendations for WHO	17
ANNEXES	1
Annex 1. List of participants, temporary advisers, observers, and Secretariat	
Annex 2. Programme of activities	

Keywords:

Laboratories / Measles / Poliomyelitis / Rubella / Vaccines

ABBREVIATIONS

AFP	acute flaccid paralysis
cVDPV	circulating vaccine-derived poliovirus
EQA	external quality assessment
ES	environmental surveillance
GAPIII	Global Action Plan to minimize poliovirus facility-associated risk after type-specific eradication of wild polioviruses and sequential cessation of oral polio vaccine use, version III
GMRLN	Global Measles and Rubella Laboratory Network
GPLN	Global Polio Laboratory Network
GSL	Global Specialized Laboratory
IgG	immunoglobulin G
IgM	immunoglobulin M
IPV	inactivated poliovirus vaccine
IRR	International Reagent Resource
ITD	intratypic differentiation
L20B	a mouse cell line (L-cells), genetically engineered to express the human poliovirus receptor
MeaNS	Measles Nucleotide Surveillance database
NIID	National Institute of Infectious Diseases
NMRL	national measles and rubella laboratory
nOPV2	novel oral polio vaccine type 2
NPEV	non-polio enterovirus
NPL	national polio laboratory
OPV	oral polio vaccine
PCR	polymerase chain reaction
PEF	poliovirus-essential facility
PIM	potentially infectious material
PT	proficiency test
PV	poliovirus
RD	human rhabdomyosarcoma
RDT	rapid diagnostic test
RNA	ribonucleic acid
RT-PCR	reverse transcriptase polymerase chain reaction
RITM	Research Institute for Tropical Medicine (Philippines)
RRL	Regional Reference Laboratory
RubeNS	Rubella Nucleotide Surveillance database
SL	Sabin-like
UNICEF	United Nations Children's Fund
US CDC	United States Centers for Disease Control and Prevention
VDPV	vaccine-derived poliovirus
VIDRL	Victorian Infectious Diseases Reference Laboratory
VPD	vaccine-preventable disease
WHO	World Health Organization
WPV	wild poliovirus

SUMMARY

The Ninth Meeting of Vaccine-Preventable Diseases Laboratory Networks in the Western Pacific Region was held virtually from 27 September to 1 October 2021 to review the performance and identify the challenges of the poliovirus and measles and rubella network laboratories in the Region.

Meeting participants reviewed ways to further strengthen the performance of network laboratories and also monitor the implementation of recommendations from the previous meeting in March 2019. The meeting provided an opportunity to address the challenges of maintaining surveillance of vaccine-preventable diseases during the coronavirus disease 2019 (COVID-19) pandemic and to discuss strengthening the quality and sensitivity of poliovirus detection, and enhancing poliovirus surveillance through increasing the sequencing capacity of national laboratories, introduction of direct virus detection and environmental surveillance in key countries and the application of the *WHO Global Action Plan to minimize poliovirus facility-associated risk after type-specific eradication of wild polioviruses and sequential cessation of oral polio vaccine use* (known as GAPIII) for the containment of poliovirus in the laboratory network. Participants also discussed: ways to improve the quality and timeliness of laboratory-based surveillance through establishing subnational laboratories, the introduction of rapid diagnostic tests for measles and rubella in countries and areas with challenging infrastructure, and the importance of molecular surveillance for support of verification of elimination of measles and rubella.

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_23404

